Weight-Loss Pills Reach a Brain Reward Circuit the Injections Miss, Dialing Down the Pleasure of Eating

The next generation of weight-loss drugs comes as a pill rather than a weekly shot, and new research suggests the pills are not simply a more convenient version of the injections. They appear to act on a part of the brain the injectables were not thought to reach.

Researchers at the University of Virginia, led by neuroscientist Ali Guler, reported in Nature this week that oral small-molecule GLP-1 drugs suppress hedonic feeding — eating for pleasure rather than hunger — by engaging the central amygdala, a deep brain structure tied to emotional processing and reward. The effect was accompanied by reduced dopamine release in the brain's reward system while animals ate palatable food.

"We've known that GLP-1 drugs suppress feeding behavior driven by energy demand," Guler said. "Now it seems oral small-molecule GLP-1s also dial back eating for pleasure by engaging a brain reward circuit."

Getting to that answer required a workaround. Small-molecule GLP-1 drugs are shaped to fit the human version of the receptor and interact poorly with the mouse version, which is why standard rodent models say little about how they behave in people. The team used gene editing to rewrite the mouse GLP-1 receptor so that it resembled the human one, then dosed the animals with orforglipron and danuglipron — the two oral candidates furthest along in human development — while recording brain activity.

The distinction between the two kinds of eating matters clinically. Injectable GLP-1 receptor agonists such as semaglutide and tirzepatide primarily blunt homeostatic feeding, the appetite that tracks the body's energy needs, largely through the gut-brain axis and hindbrain circuits. Hedonic feeding — the pull of a dessert after a full meal, or the late-night trip to the refrigerator — runs on separate reward machinery, and it is a common reason weight returns when patients stop treatment. A drug that reaches both systems could work differently over the long run, and the amygdala's role in emotional processing raises questions researchers are already asking about mood and craving more broadly.

Lorenzo Leggio, clinical director of the National Institute on Drug Abuse, supported the work; NIDA has been tracking GLP-1 drugs closely because of scattered reports that patients on them also drink and smoke less, which would fit a reward-circuit mechanism. The caveats are the usual ones for a mouse study, even a humanized one: the receptors were engineered, the doses were experimental, and behavior in a cage is not behavior in a kitchen. Both orforglipron and danuglipron are in late-stage human trials, and this study offers a specific brain circuit for those trials to look for evidence of.